GlassScriptPhysician profile
Jake Michael Rockman
NPI 1780099317
$8,430.58
in general payments reported to CMS, 2019-2025
24 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $1,187 · 2021: $2,155 · 2022: $1,138 · 2023: $1,253 · 2024: $769 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,999 · Entertainment: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.75 |
| Entertainment | $352.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,488.02 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,547.92 | 2019-2021 | |
| Optos, INC. | $747.62 | 2019-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Coopervision INC. | $582.78 | 2019-2024 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $552.02 | 2022-2024 | Biotrue One Day, Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $532.38 | 2019-2023 | Acuvue |
| Biotissue Holdings INC. | $331.51 | 2021-2024 | |
| Sight Sciences, INC. | $324.11 | 2022-2025 | Omni Surgical System, Tearcare System |
| Abbvie INC. | $225.35 | 2022-2023 | Durysta, Lumigan, Alphagan P |
| Astellas Pharma US INC | $223.45 | 2023-2025 | Izervay |
| Ocular Therapeutix, INC. | $200.94 | 2022 | |
| Dompe US, INC. | $121.45 | 2021 | |
| Maculogix, INC. | $105.03 | 2020 | |
| Optovue, INC. | $88.06 | 2021 | |
| Amgen INC. | $84.48 | 2024 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $67.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $58.80 | 2022-2023 | |
| Visionix USA, INC | $35.18 | 2022 | |
| Oyster Point Pharma, INC. | $21.43 | 2022 | |
| Rxsight INC | $21.08 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Horizon Therapeutics Plc | $18.81 | 2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $18.43 | 2021 | |
| Aerie Pharmaceuticals, INC. | $17.97 | 2019 | |
| Shire North American Group INC | $15.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Rockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.